Figure 1.
N‐{3‐[(1,4′‐bipiperidin)‐1′‐yl]propyl}‐6‐[4‐(4‐methylpiperazin‐1‐yl)phenyl]picolinamide, STING‐mediated interferon‐inducing and cytotoxic reagent, original (SINCRO) induces interferon‐β (IFN‐β) expression in cancer cells and immune cells. A, Structural formula of SINCRO is shown. B, B16F1 cells (8 × 104 cells) were treated with SINCRO (10 μg/mL) for the indicated time. IFN‐β mRNA expression was quantified by qRT‐PCR analysis. C,D, B16F1 cells (8 × 104 cells) were cultured in the presence of SINCRO (2.5, 5 or 10 μg/mL), DMSO, or B‐DNA (10 μg/mL; B). C, IFN‐β mRNA expression was determined by qRT‐PCR analysis after incubation for 9 h. D, IFN‐β protein levels in the culture supernatant were measured by ELISA after 24 h treatment. E, EL4 cells (5 × 105 cells), SL4 cells (8 × 104 cells), HBC4 cells (8 × 104 cells), or HeLa cells (8 × 104 cells) were treated with SINCRO (10 μg/mL) for the indicated period. IFN‐β mRNA levels were quantified by qRT‐PCR analysis. F, Bone marrow‐derived dendritic cells (BMDC; 5 × 105 cells) or peritoneal macrophages (5 × 105 cells) were treated with SINCRO (10 μg/mL). IFN‐β mRNA levels at the indicated time points were quantified by qRT‐PCR analysis. Data are shown as mean ± SEM